Literature DB >> 7727729

Cancer cytogenetics and molecular genetics: detection and therapeutic strategy.

A A Sandberg1, Z Chen.   

Abstract

It has become increasingly evident that cancers are "genetic diseases" resulting from an accumulation of inherited and environmentally-induced changes or mutations in the genome, i.e., the modification, activation, or inactivation of various genes, including oncogenes, tumor-suppressor genes, and genes related to cell death. Cancer genetics has, therefore, become a burgeoning area of both cytogenetic/molecular genetic research and practical clinical application in human cancer. This article summarizes the specific types of chromosomal and associated molecular genetic alterations in leukemia and cancer. The emphasis is on the application of cytogenetics and molecular cytogenetics as diagnostic, prognostic and therapeutic indices, as approaches to the evaluation of minimal residual disease and as guides for differentiation therapy and the molecular localization of oncogenes/tumor suppressor genes related to gene therapy in leukemias and cancers. This review is intended to update physicians of various disciplines on the rapid advances that have been made in the understanding of the chromosomal and molecular basis of cancer and in approaches for improving the management of cancer patients through knowledge of genetics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7727729

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  Mechanisms underlying losses of heterozygosity in human colorectal cancers.

Authors:  S Thiagalingam; S Laken; J K Willson; S D Markowitz; K W Kinzler; B Vogelstein; C Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

2.  Cytogenetic analyses of secondary liver tumors reveal significant differences in genomic imbalances between primary and metastatic colon carcinomas.

Authors:  L A Parada; A Marañon; M Hallén; K G Tranberg; U Stenram; G Bardi; B Johansson
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.